The therapeutic revolution in therapy for hepatitis C (HCV) seen in recent years has left some critical gaps with genotypes other than 1 have either lesser evidence of efficacy or proven lower efficacy. Even with the potential availability of drugs with cure rates approaching 100% it is uncertain how many populations across the world will have the finance and the health system organization to access these therapies.